EVENTS | VIEW CALENDAR
Quest Diagnostics gets FDA clearance for molecular diagnostics-based H1N1 test
MADISON, N.J., and CYPRESS, Calif.—Quest Diagnostics Inc., a provider of diagnostic testing, information and services, announced May 24 that the U.S. Food and Drug Administration (FDA) has issued 510(k) clearance to the Simplexa Influenza A H1N1 (2009) test on the 3M Integrated Cycler. The Simplexa test, developed and manufactured by Quest Diagnostics' Focus Diagnostics business, is the first to be cleared by the FDA for use as an aid in the detection and differentiation of influenza A and 2009 H1N1 influenza viral RNA.
The Simplexa Influenza A H1N1 (2009) test runs on the 3M Integrated Cycler under an exclusive global distribution agreement between Focus Diagnostics and 3M. The test employs real-time reverse transcription (RT) polymerase chain reaction (PCR) to qualitatively detect RNA of the 2009 H1N1 flu virus (2009 H1N1) in a patient's nasal or nasopharyngeal specimens. It reports if a specimen is positive or negative for the presence of 2009 H1N1 or influenza A virus. By comparison, some flu tests, including rapid point-of-care influenza tests, can detect the presence of influenza A, but not differentiate the presence of 2009 H1N1. In addition to 2009 H1N1, influenza A viruses include some seasonal flu subtypes.
"Thankfully, H1N1 is not currently a widespread public health problem, but reliable detection continues to be important to help manage high-risk patients, such as expectant mothers who have flu-like symptoms," says Dr. Jay M. Lieberman, medical director, infectious diseases for Quest Diagnostics and Focus Diagnostics. "Influenza viruses are unpredictable, and reliable tests will be needed, particularly if, as expected, 2009 H1N1 activity again increases later this year."
"Innovation often emerges in response to crisis, and the 2009 H1N1 is no exception," adds Dr. John G. Hurrell, vice president and general manager of Focus Diagnostics. "When 2009 H1N1 surfaced about a year ago, limitations in traditional flu tests made them unsuitable for dealing with a virus infecting large swaths of the population. These limitations included the sensitivity of rapid tests and the need to ship samples to reference labs with reliable PCR methods. We designed our Simplexa 2009 H1N1 test to overcome these problems by bridging highly reliable PCR with testing technologies that many hospital labs can perform in-house."
"Moreover, FDA clearance of our Simplexa test means hospital and other labs can use our test with confidence since it meets regulatory requirements long term, unlike flu tests authorized for 2009 H1N1 emergency use testing until late June," Hurrell notes.